SCA
UTHR icon

Snowden Capital Advisors’s United Therapeutics UTHR Stock Holding History

Snowden Capital Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$552K Buy
1,019
+526
+107% +$296K 0.01% 801
2026
Q1 		$292K Sell
493
-23
-4% -$11.5K 0.01% 1044
2025
Q4 		$251K Buy
+516
New +$240K 0.01% 1119

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Snowden Capital Advisors's UTHR Position: Q2 2026 in Review

Snowden Capital Advisors increased its United Therapeutics (UTHR) stake by 107% in Q2 2026, buying an estimated $296K and bringing the position to 1,019 shares worth $552K. The position accounts for 0.01% of the portfolio, ranked #801.

Snowden Capital Advisors first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Snowden Capital Advisors held 1,019 shares of United Therapeutics worth $552K as of Q2 2026.
  • Snowden Capital Advisors bought 526 United Therapeutics shares in Q2 2026, an estimated $296K.
  • United Therapeutics made up 0.01% of Snowden Capital Advisors's portfolio in Q2 2026, its #801 holding.
  • Snowden Capital Advisors first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Snowden Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.